ALNYLAM PHARMACEUTICALS INC
NASDAQ: ALNY (Alnylam Pharmaceuticals, Inc.)
Last update: 10 hours ago246.78
-4.70 (-1.87%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Alnylam Pharmaceuticals, Inc. | Bullish | Bullish |
Stockmoo Score
|
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 400.00 (HC Wainwright & Co., 62.09%) | Buy |
| Median | 291.50 (18.12%) | |
| Low | 159.00 (Leerink Partners, -35.57%) | Hold |
| Average | 289.22 (17.20%) | |
| Total | 13 Buy, 5 Hold | |
| Avg. Price @ Call | 255.34 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 04 Sep 2024 | 307.00 (24.40%) | Buy | 253.14 |
| 25 Jun 2024 | 295.00 (19.54%) | Buy | 240.15 | |
| RBC Capital | 04 Sep 2024 | 300.00 (21.57%) | Buy | 253.14 |
| 02 Aug 2024 | 300.00 (21.57%) | Buy | 272.05 | |
| HC Wainwright & Co. | 30 Aug 2024 | 400.00 (62.09%) | Buy | 262.69 |
| 20 Aug 2024 | 400.00 (62.09%) | Buy | 280.76 | |
| JP Morgan | 26 Aug 2024 | 280.00 (13.46%) | Hold | 269.14 |
| 03 Jul 2024 | 248.00 (0.49%) | Hold | 248.68 | |
| Goldman Sachs | 16 Aug 2024 | 370.00 (49.93%) | Buy | 268.24 |
| 02 Aug 2024 | 198.00 (-19.77%) | Hold | 272.05 | |
| Barclays | 02 Aug 2024 | 295.00 (19.54%) | Buy | 272.05 |
| 25 Jun 2024 | 291.00 (17.92%) | Buy | 240.15 | |
| Canaccord Genuity | 02 Aug 2024 | 366.00 (48.31%) | Buy | 272.05 |
| 08 Jul 2024 | 357.00 (44.66%) | Buy | 255.11 | |
| Citigroup | 02 Aug 2024 | 342.00 (38.58%) | Buy | 272.05 |
| 25 Jun 2024 | 291.00 (17.92%) | Buy | 240.15 | |
| Needham | 02 Aug 2024 | 320.00 (29.67%) | Buy | 272.05 |
| 24 Jun 2024 | 275.00 (11.44%) | Buy | 222.90 | |
| Wells Fargo | 02 Aug 2024 | 233.00 (-5.58%) | Hold | 272.05 |
| 25 Jun 2024 | 207.00 (-16.12%) | Hold | 240.15 | |
| Cantor Fitzgerald | 22 Jul 2024 | 220.00 (-10.85%) | Hold | 235.59 |
| 01 Jul 2024 | 150.00 (-39.22%) | Hold | 243.32 | |
| Morgan Stanley | 12 Jul 2024 | 255.00 (3.33%) | Hold | 260.51 |
| 25 Jun 2024 | 250.00 (1.30%) | Hold | 240.15 | |
| UBS | 28 Jun 2024 | 288.00 (16.70%) | Buy | 243.00 |
| Stifel | 27 Jun 2024 | 295.00 (19.54%) | Buy | 247.00 |
| Evercore ISI Group | 25 Jun 2024 | 260.00 (5.36%) | Buy | 240.15 |
| Leerink Partners | 25 Jun 2024 | 159.00 (-35.57%) | Hold | 240.15 |
| TD Cowen | 25 Jun 2024 | 282.00 (14.27%) | Buy | 240.15 |
| BMO Capital | 24 Jun 2024 | 234.00 (-5.18%) | Buy | 222.90 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |